Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 70c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Castle Biosciences Reports Second Quarter 2022 Results
August 8, 2022 4:05 PM EDT
Q2 2022 revenue increased 53% over Q2 2021 to $34.8 million
Delivered 11,034 total test reports in Q2 2022, an increase of 57% compared to Q2 2021
Skin cancer gene expression profile test report volume increased 44% compared to Q2 2021
Raising 2022 Revenue Guidance to $130135 million from $118123 million
Conference call and webcast today at 4:30 p.m. ET
FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter and six months ended... More
